GALE 302

Drug Profile

GALE 302

Alternative Names: Attenuated E39 peptide vaccine - Sellas Life Sciences Group; E39 prime vaccine - Sellas Life Sciences Group; E39'; E39'-GM-CSF-vaccine - Sellas Life Sciences Group; EIWTFSTKV; FBP-J65; Folate binding protein J65 - Sellas Life Sciences Group; GALE-302; J65

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galena Biopharma
  • Developer Sellas Life Sciences Group
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides; Stem cell therapies
  • Mechanism of Action Folate receptor 1 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Ovarian cancer

Most Recent Events

  • 29 Dec 2017 Galena Biopharma merged with Sellas Life Sciences and subsequently changed its name to Sellas Life Sciences Group
  • 03 May 2017 GALE 302 is still at phase I/II development stage for Breast cancer and Ovarian cancer (Combination therapy, Adjuvant therapy, Prevention of relapse) in USA (Intradermal) (Galena Biopharma pipeline, May 2017)
  • 09 Mar 2017 COL George Peoples and M.D. Anderson Cancer Center completes a phase Ib/II trial in Breast cancer and Ovarian cancer (Prevention of relapse, Adjuvant therapy, Combination therapy) in USA before March 2017 (NCT02019524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top